TARSUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.04 USD | -0.53% |
|
-1.23% | +58.22% |
| 24/04 | BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals | MT |
| 24/04 | BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals | AN |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 839.8 | 465.2 | 391 | 670.4 | 1,210 | - | - |
| Enterprise Value (EV) 1 | 839.8 | 465.2 | 391 | 472.1 | 1,128 | 1,180 | 1,064 |
| P/E ratio | -9.57 x | -33.6 x | -5.82 x | -4.38 x | -7.6 x | -15 x | 35.1 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 8.16 x | 15.1 x | 38.4 x | 11.7 x | 5.84 x | 3.4 x |
| EV / Revenue | - | 8.16 x | 15.1 x | 27.1 x | 10.9 x | 5.69 x | 2.99 x |
| EV / EBITDA | -31.2 x | -39.3 x | -6.27 x | -3.32 x | -8.54 x | -14.6 x | 29.9 x |
| EV / FCF | -3,88,92,433 x | 14,71,32,296 x | - | - | - | - | - |
| FCF Yield | -0% | 0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,320 | 20,677 | 26,672 | 33,105 | 37,777 | - | - |
| Reference price 2 | 41.33 | 22.50 | 14.66 | 20.25 | 32.04 | 32.04 | 32.04 |
| Announcement Date | 31/03/21 | 14/03/22 | 13/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 57.03 | 25.82 | 17.45 | 103.3 | 207.3 | 356.4 |
| EBITDA 1 | -26.9 | -11.84 | -62.39 | -142.3 | -132.1 | -80.84 | 35.61 |
| EBIT 1 | -27 | -12.16 | -62.71 | -143.2 | -149.6 | -79.93 | 41.11 |
| Operating Margin | - | -21.32% | -242.92% | -820.53% | -144.82% | -38.55% | 11.54% |
| Earnings before Tax (EBT) 1 | -26.81 | -13.77 | -62.1 | -135.9 | -143.4 | -79.3 | 40.16 |
| Net income 1 | -26.81 | -13.83 | -62.09 | -135.9 | -145.1 | -77.76 | 39.75 |
| Net margin | - | -24.25% | -240.51% | -778.89% | -140.52% | -37.51% | 11.15% |
| EPS 2 | -4.320 | -0.6700 | -2.520 | -4.620 | -4.217 | -2.132 | 0.9125 |
| Free Cash Flow | -21.59 | 3.162 | - | - | - | - | - |
| FCF margin | - | 5.54% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 31/03/21 | 14/03/22 | 13/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.24 | 0.338 | 0.539 | 15.28 | - | 10 | 2.5 | - | 1.871 | 13.08 | 17.9 | 22.85 | 27.36 | 33.83 |
| EBITDA | -15.62 | -14.41 | -19.48 | -5.132 | -22.81 | -14.96 | -24.85 | -32.64 | - | -44.1 | - | - | - | - |
| EBIT 1 | -15.7 | -14.45 | -19.52 | -5.224 | -22.91 | -15.06 | -24.95 | -32.82 | -40.94 | -44.45 | -40.8 | -38.91 | -36.2 | -33.3 |
| Operating Margin | -1,266.53% | -4,274.56% | -3,621.71% | -34.2% | - | -150.61% | -998.08% | - | -2,187.87% | -339.94% | -227.95% | -170.31% | -132.3% | -98.43% |
| Earnings before Tax (EBT) 1 | -16.04 | -14.8 | -20.24 | -5.743 | -22.52 | -13.6 | -23.42 | -31.42 | -39.15 | -41.9 | -41.92 | -39.22 | -37.97 | -36.23 |
| Net income 1 | -15.7 | -14.85 | -20.24 | -5.743 | -22.51 | -13.6 | -23.42 | -31.42 | -39.15 | -41.9 | -39.16 | -37.89 | -35.76 | -32.87 |
| Net margin | -1,265.89% | -4,393.79% | -3,754.73% | -37.59% | - | -135.99% | -936.76% | - | -2,092.36% | -320.45% | -218.81% | -165.85% | -130.69% | -97.19% |
| EPS 2 | -0.7600 | -0.7200 | -0.9800 | -0.2400 | -0.8400 | -0.4900 | -0.8800 | -1.170 | -1.280 | -1.310 | -1.190 | -1.108 | -1.033 | -0.9350 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 09/11/21 | 14/03/22 | 10/05/22 | 11/08/22 | 09/11/22 | 13/03/23 | 09/05/23 | 10/08/23 | 09/11/23 | 27/02/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 198 | 82.5 | 30.6 | 146 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -21.6 | 3.16 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -33.5% | -8.31% | -34.5% | -69.7% | -77.8% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | -3.410 | 0.1800 | -1.990 | -4.000 | -2.890 | -1.120 | - |
| Capex | 0.46 | 0.59 | 0.51 | - | - | - | - |
| Capex / Sales | - | 1.03% | 1.96% | - | - | - | - |
| Announcement Date | 31/03/21 | 14/03/22 | 13/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
32.04
USD
Average target price
52.44
USD
Spread / Average Target
+63.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +58.22% | 1.21B | |
| +25.83% | 661B | |
| +26.43% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.72% | 231B | |
| +5.26% | 200B | |
| -8.79% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- TARS Stock
- Financials Tarsus Pharmaceuticals, Inc.
